Medrad Introduces New Extravasation Detector Technology

Medrad Inc. introduced at the American Healthcare Radiology Administrators (AHRA) Annual Meeting the XDS, a new extravasation detector technology for the Stellant CT Injection System that, for the first time, directly senses extravasation pooling under the skin during a CT procedure.
The Medrad XDS extravasation detector is a patented product designed to prevent moderate to severe contrast extravasations that may seriously injure patients. Using radio frequency (RF) wave technology and a physical property called permittivity, XDS can detect the start of an extravasation under the patient’s skin and signal the Stellant to stop injecting until a clinician can examine the patient.